Sign in
Taking people in United StatesPhase 1/2

Testing CM4620 to lessen pancreatitis caused by asparaginase in young patients

Tests CM4620 in children and young adults with asparaginase-caused pancreatitis.

Key facts

Who runs it
St. Jude Children's Research Hospital
Where
Charlotte, Cincinnati, and Memphis, United StatesSee the 3 sites
Trial code
Registry title
Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Status
Recruiting
Phase
Phase 1/2
People taking part
42 people, planned
Started
4 Sept 2020
Expected to end
Jan 2029
Type of study
Interventional
Treatments tested
  • CM4620
Record updated
3 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children and young people with acute lymphoblastic leukemia or lymphoma who developed acute pancreatitis after asparaginase. It tests the drug CM4620.

Age
Under 22 years (maximum age 21 years)
Sex
All sexes can join.
Disease stage
Acute pancreatitis with amylase or lipase at least 3 times the upper limit of normal, plus abdominal pain or imaging signs of pancreatitis. Acute lymphoblastic leukemia or lymphoma treated with treatment meant to remove all of the disease.
Earlier treatment
Must have received any form of asparaginase within the last 49 days. Must not have received another investigational drug in the last 7 days.

Main reasons for not taking part

  • A previous episode of pancreatitis
  • QTc above 450 msec at the start
  • Creatinine or total bilirubin above 3 times the upper limit of normal for age, without leukemic infiltrate or hemolysis
  • Allergy to eggs or known hypersensitivity to any component of CM4620
  • Positive pregnancy test or breastfeeding

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Acute pancreatitis with elevation of amylase OR lipase ≥ 3x the upper limit of normal AND at least 1 of: abdominal pain consistent with acute pancreatitis OR imaging findings consistent with acute pancreatitis
  • Receipt of any form of asparaginase within the prior 49 days
  • Patient with acute lymphoblastic leukemia/ lymphoma age < 22 years receiving therapy with curative intent

Who cannot take part

  • Prior episode of pancreatitis
  • Receipt of another investigational agent within the prior 7 days
  • History of allergy to eggs or known hypersensitivity to any component of CM4620
  • QTc at baseline > 450 msec
  • Creatinine > 3x the upper limit of normal for age or total bilirubin >3x the upper limit for normal for age without evidence of leukemic infiltrate or hemolysis
  • Positive pregnancy test or breastfeeding. Females of childbearing potential must have a negative urine or serum pregnancy test prior to enrollment. Males and females of childbearing potential must agree to use effective contraception for at least twelve months following the completion of therapy
  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent

Where in United States

  • Novant Health Presbyterian Hemby Children's HospitalCharlotte, United StatesContact: Jessica Bell, MDTaking people
  • Cincinnati Children's Hospital Medical CenterCincinnati, United StatesContact: Robin Morris, MDTaking people
  • St. Jude Children's Research HospitalMemphis, United StatesContact: Seth E. Karol, MDTaking people

About the trial

What the trial wants to find out

This is a phase I/II clinical trial assessing the tolerability and efficacy of CM4620 in children and young adults with acute pancreatitis caused by asparaginase. The tolerability of CM4620 when given to patients receiving frontline chemotherapy will be determined. The effectiveness in reducing the severity of pancreatitis will be estimated.

Read full original descriptionShow less

Primary Objectives

To assess the safety of CM4620 administration in children and young adults with asparaginase associated pancreatitis (AAP).

To profile dose-limiting toxicities and responses of the patients treated in the dose-finding phase.

To estimate the efficacy of CM4620 to prevent pseudocyst or necrotizing pancreatitis in children with AAP.

Secondary Objectives

To determine the effect of CM4620 on the incidence of severe pancreatitis

To determine the effect of CM4620 on the incidence of Systemic Inflammatory Response Syndrome (SIRS).

The group in the trial

  • CM4620 TreatmentTreatment being tested

    Phase I: Cohort 1 patients receive CM4620 IV at dose level 1 on days 1-4. Cohort 2 patients receive CM4620 IV at dose level 2 on days 1-4. Cohort 3 patients receive CM4620 IV at either dose level 1 or 2 on days 1-4 Phase II: Patients will receive CM4620 IV on days 1-4 at the recommended Phase II dose (RP2D) as determined in Phase I.

    Treatment: CM4620

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
CRSPA: Phase I/II Study of CM4620 to Reduce the Severity of Pancreatitis Due to Asparaginase
Plain-language title
Testing CM4620 to lessen pancreatitis caused by asparaginase in young patientsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 June 2026